FI925210A0 - Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda - Google Patents

Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda

Info

Publication number
FI925210A0
FI925210A0 FI925210A FI925210A FI925210A0 FI 925210 A0 FI925210 A0 FI 925210A0 FI 925210 A FI925210 A FI 925210A FI 925210 A FI925210 A FI 925210A FI 925210 A0 FI925210 A0 FI 925210A0
Authority
FI
Finland
Prior art keywords
modification
rna molecular
rna
aenda
foerfaranden
Prior art date
Application number
FI925210A
Other languages
English (en)
Other versions
FI925210A (fi
Inventor
Brenda F Baker
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of FI925210A publication Critical patent/FI925210A/fi
Publication of FI925210A0 publication Critical patent/FI925210A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
FI925210A 1990-05-23 1992-11-17 Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda FI925210A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52759990A 1990-05-23 1990-05-23
PCT/US1991/003606 WO1991017755A1 (en) 1990-05-23 1991-05-22 Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna

Publications (2)

Publication Number Publication Date
FI925210A FI925210A (fi) 1992-11-17
FI925210A0 true FI925210A0 (fi) 1992-11-17

Family

ID=24102143

Family Applications (1)

Application Number Title Priority Date Filing Date
FI925210A FI925210A0 (fi) 1990-05-23 1992-11-17 Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda

Country Status (15)

Country Link
EP (1) EP0531447B1 (fi)
JP (1) JPH06500075A (fi)
KR (1) KR960004931B1 (fi)
AT (1) ATE186464T1 (fi)
AU (1) AU649458B2 (fi)
BR (1) BR9106486A (fi)
CA (1) CA2083377C (fi)
DE (1) DE69131773T2 (fi)
DK (1) DK0531447T3 (fi)
ES (1) ES2139578T3 (fi)
FI (1) FI925210A0 (fi)
GR (1) GR3032457T3 (fi)
HU (1) HUT63568A (fi)
NO (1) NO924309D0 (fi)
WO (1) WO1991017755A1 (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
WO1994022488A1 (en) * 1993-04-01 1994-10-13 Isis Pharmaceuticals, Inc. ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION
IL114235A0 (en) * 1994-07-14 1995-10-31 Schering Ag Oligonucleotide conjugates and processes for noninvasive diagnosis utilizing the same
US6380169B1 (en) * 1994-08-31 2002-04-30 Isis Pharmaceuticals, Inc. Metal complex containing oligonucleoside cleavage compounds and therapies
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
WO2001062981A1 (en) * 2000-02-25 2001-08-30 Montclair Group Platform for the discovery of the bacterial genes involved in rna modification
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
KR101835401B1 (ko) 2012-07-13 2018-03-08 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. 키랄 핵산 어쥬번트
ES2940887T3 (es) 2012-07-13 2023-05-12 Wave Life Sciences Ltd Método de preparación de oligonucleótidos quirales
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
KR927003044A (ko) * 1990-01-11 1992-12-17 크리스토퍼 케이. 미라벨리 Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법

Also Published As

Publication number Publication date
AU8080291A (en) 1991-12-10
HUT63568A (en) 1993-09-28
NO924309L (no) 1992-11-09
DK0531447T3 (da) 2000-03-27
ATE186464T1 (de) 1999-11-15
EP0531447A4 (en) 1993-08-11
NO924309D0 (no) 1992-11-09
CA2083377C (en) 2002-11-26
DE69131773D1 (de) 1999-12-16
FI925210A (fi) 1992-11-17
EP0531447B1 (en) 1999-11-10
HU9203659D0 (en) 1993-04-28
BR9106486A (pt) 1993-05-25
JPH06500075A (ja) 1994-01-06
EP0531447A1 (en) 1993-03-17
WO1991017755A1 (en) 1991-11-28
CA2083377A1 (en) 1991-11-24
GR3032457T3 (en) 2000-05-31
KR960004931B1 (ko) 1996-04-18
AU649458B2 (en) 1994-05-26
KR930700118A (ko) 1993-03-13
DE69131773T2 (de) 2000-03-02
ES2139578T3 (es) 2000-02-16

Similar Documents

Publication Publication Date Title
FI925210A0 (fi) Kompositioner och foerfaranden foer modulering av rna-molekylens aktivitet genom modifiering av cap-strukturen i rna-molekylens 5'-aenda
DE69433626D1 (de) N-2 substituierte purine
DE69322640T2 (de) Bindungskompetente oligomere, die 2',5'-bindungen enthalten
WO1998011243A3 (en) Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein
DE3280400D1 (de) Oligonukleotides heilmittel und dessen herstellungsverfahren.
ATE230439T1 (de) Gezielte gentherapie
DE69634698D1 (de) Gewebespezifische und ziel-rna-spezifische ribozyme
MA20411A1 (fr) Procede de preparation de polypeptides ayant l'activite du gamma-interferon humain
KR920004570A (ko) 사람 mk 단백질을 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, mk단백질의 생산 방법 및 사용방법
FI103577B1 (fi) Menetelmä, DNA ja mikro-organismi trombolyyttisen aineen valmistamiseksi
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
WO2000029589A8 (en) Methioninase gene therapy for tumor treatment
DE69331216T2 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
AU7974791A (en) Identification of novel drugs and reagents
ATE218372T1 (de) Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren
DE69433996D1 (de) Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten
DK1235916T3 (da) Isolerede polynukleotider med et formindsket indhold af 5'CpG3' epigenitiske kontrolmotiver og anvendelser deraf
WO1993013204A3 (de) Mittel zur stimulierung der teilungsaktivität tierischer zellen
WO1999027088A3 (en) Novel gene and protein expressed in neural and pancreatic tissues
AU2782989A (en) Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
Gallagher et al. Enzymic cleavage of purine ultraviolet photoproducts formed at biologically significant wavelengths
RU98104062A (ru) Контроль экспрессии гена cd44 для терапевтического применения

Legal Events

Date Code Title Description
FD Application lapsed